Perioperative immunotherapy in head and neck squamous cell carcinoma
Cancer · 2026
DOI: 10.1002/cncr.70642 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, 2026. Verfasst von Marius Hörner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Plastic-Head and Neck Surgery, University Hospital of Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Immunotherapy, Squamous Cell Carcinoma of Head and Neck, Immune Checkpoint Inhibitors. Die Arbeit nennt 61 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Outcomes for patients with resectable head and neck squamous cell carcinoma (HNSCC) remain suboptimal despite multimodal therapy, with high rates of recurrence and patients suffering from toxicity of treatments. Immune checkpoint inhibitors, which have transformed the management of recurrent and metastatic disease, have been advanced into the perioperative and adjuvant settings. Recent phase III trials mark a turning point: the addition of adjuvant nivolumab improved disease‐free survival in pathologic high‐risk resected HNSCCs, while perioperative pembrolizumab significantly prolonged event‐free survival in resectable locally advanced HNSCCs, supporting a shift toward integrated perioperative immunotherapy strategies. Although the former approach fits into a conventional adjuvant framework, biological insights suggest that neoadjuvant delivery enables effective immune priming extending therapeutic approaches. Together, these advances redefine therapeutic strategies in resectable HNSCC and highlight the potential of perioperative immunotherapy to improve long‐term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Plastic-Head and Neck Surgery, University Hospital of Würzburg, Würzburg, Germany.
- Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Division of Medical Oncology Washington University School of Medicine, Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Alvin J. Siteman Cancer Center, and Barnes Jewish Hospital, St. Louis, Missouri, USA.
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Ravindra Uppaluri
Förderung
- None
Zitieren
APA
Hörner, M., Hartmann, S., Adkins, D. R., & Uppaluri, R. (2026). Perioperative immunotherapy in head and neck squamous cell carcinoma. Cancer. https://doi.org/10.1002/cncr.70642
Vancouver
Hörner M, Hartmann S, Adkins DR, Uppaluri R. Perioperative immunotherapy in head and neck squamous cell carcinoma. Cancer. 2026. doi:10.1002/cncr.70642
BibTeX
@article{Hrner2026,
author = {Hörner, Marius and Hartmann, Stefan and Adkins, Douglas R and Uppaluri, Ravindra},
title = {Perioperative immunotherapy in head and neck squamous cell carcinoma},
journal = {Cancer},
year = {2026},
doi = {10.1002/cncr.70642}
}
EUVIMED